CGON - CG Oncology, Inc. Common stock
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$82.57
DETAILS
HIGH:
$93.00
LOW:
$70.00
MEDIAN:
$82.00
CONSENSUS:
$82.57
UPSIDE:
28.51%
About CG Oncology, Inc. Common stock (https://cgoncology.com)
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Arthur Kuan | Chairman & Chief Executive Officer | 1991 | $1,126,002 USD |
| Ambaw Bellete | President & Chief Operating Officer | 1971 | $847,791 USD |
| James DeTore | Chief Financial Officer | 1965 | $785,472 USD |
| Vijay Kasturi | Chief Medical Officer | 1968 | $759,983 USD |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | 1977 | $693,819 USD |
| Amy Steele | Vice President of Finance & Administration | – | – |
| Bing Kung | Vice President of Corporate Development | – | – |
| Sarah Connors | Vice President of Communications & Patient Advocacy | – | – |
| Swapnil Bhargava | Chief Technical Officer | – | – |